XT381: A Next-Generation PSMA-Targeted Radioligand with Enhanced Tumor Retention and Efficacy (EANM 2026) - Sep 29, 2026 - Abstract #EP-0168; "[177Lu]Lu-XT381 is more efficacious than [177Lu] Lu-PSMA-617 in inhibiting tumor growth, while maintaining a comparable safety margin."
Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1
|
|
G. Zhang 1; J. Zhu 1; Y. Zhou 2; L. Fu 1; Z. Zhao 1; Y. Shi 1; H. Ma 1; L. Qian 2; X. Zhong 1
|